Follow-Up Viaskin Peanut Patch Data Shows Cross-Contamination Benefit
MARCH 23, 2020
Todd Green, MD
In an interview with HCPLive®, Todd Green, MD, Vice President of Clinical Development and Medical Affairs at DBV Technologies and author of the "Open-Label Follow-Up of the PEPITES Study (PEOPLE) to Evaluate the Long-Term Efficacy and Safety of Epicutaneous Peanut Immunotherapy in Peanut-Allergic Children," explained how the Viaskin Peanut 250 μg could help eliminate the cross-contamination concern.
“This is designed to try to desensitize patients, which means increase how much they can eat before they have a reaction,” Green said. “If you can increase someone’s threshold then you can decrease their chance of having a reaction.”
Green was expected to present data during the American Academy of Allergy, Asthma & Immunology (AAAAI) 2020 Annual Meeting in Philadelphia, PA, but the conference was cancelled due to the coronavirus disease 2019 (COVID-19) outbreak.
The study included peanut allergy children who were initially enrolled in the phase 3 study and completed the 12-month double-blind placebo controlled food challenge at the conclusion of the PEPITES study.
The original study included 2 groups of patients, a group treated with a placebo patch and a group treated with the 250 microgram patch, which roughly the equivalent of 1/1000 of a peanut.
“So, the goal of our epicutaneous immunotherapy is to try to increase the amount that you have allergic patients can eat before they experience their reaction,” Green said. “Because if you can do that you decrease somebody's risk of having a reaction to an accidental ingestion.”
At month 12, the starting dose for the food challenge was 1 mg of peanut protein, with escalation up to the highest dose of 2000 mg to reach a maximum total cumulative dose of 3444 mg of peanut protein.
At month 36, 51.8% of the subjects reached an ED of ≥1000 mg, compared with 40.4% at month 12 (11.3% difference; 95% CI, 2.8-19.6).
The investigators sought primary outcomes of the percentage of subjects in the VP250+VP250 group who reached an ED of ≥1000 mg after 36 months of active treatment, and the difference between this and the percentage of subjects reaching an eliciting dose of ≥1000 mg after 12 months of active treatment.
They also sought additional endpoints of the change from baseline to 36 months in eliciting dose and in cumulative reactive dose, safety outcomes, changes in immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) over the 3-year period, and SU assessment.
Overall, an increase in eliciting dose from PEPITES baseline to month 36 was observed in 75.9% of subjects and of the participants with baseline ED ≤100 mg, 67.4% reached an eliciting dose of at least 300 mg.
After 36 months, the mean cumulative reactive dose was 1768.8 mg, roughly the equivalent of 6 peanuts.
The study represents the largest long-term peanut allergy immunotherapy trial.
Some of the side effects and adverse events found in individuals using the patch include local reactions at the site of the patch, both itching and redness. However, despite the local reactions the investigators said they were manageable with an antihistamine, which is shown by the 98% compliance rate in the study. Also no treatment-related epinephrine use occurred.
The application for the new patch was accepted by the US Food and Drug Administration (FDA) in 2019 for review and there is a target action date currently set for August.